全文获取类型
收费全文 | 902586篇 |
免费 | 63796篇 |
国内免费 | 2334篇 |
学科分类
医药卫生 | 968716篇 |
出版年
2018年 | 9149篇 |
2017年 | 7225篇 |
2016年 | 7760篇 |
2015年 | 8838篇 |
2014年 | 12498篇 |
2013年 | 19385篇 |
2012年 | 25964篇 |
2011年 | 27623篇 |
2010年 | 16770篇 |
2009年 | 15918篇 |
2008年 | 26449篇 |
2007年 | 28103篇 |
2006年 | 28238篇 |
2005年 | 27777篇 |
2004年 | 26666篇 |
2003年 | 25815篇 |
2002年 | 25414篇 |
2001年 | 41669篇 |
2000年 | 42912篇 |
1999年 | 36534篇 |
1998年 | 10049篇 |
1997年 | 9170篇 |
1996年 | 8473篇 |
1995年 | 8445篇 |
1994年 | 8087篇 |
1993年 | 7594篇 |
1992年 | 28326篇 |
1991年 | 27129篇 |
1990年 | 26529篇 |
1989年 | 25495篇 |
1988年 | 23657篇 |
1987年 | 23278篇 |
1986年 | 22371篇 |
1985年 | 21278篇 |
1984年 | 15868篇 |
1983年 | 13542篇 |
1982年 | 8082篇 |
1979年 | 14636篇 |
1978年 | 10222篇 |
1977年 | 8637篇 |
1976年 | 8152篇 |
1975年 | 8979篇 |
1974年 | 10702篇 |
1973年 | 10186篇 |
1972年 | 9689篇 |
1971年 | 8941篇 |
1970年 | 8611篇 |
1969年 | 8038篇 |
1968年 | 7705篇 |
1967年 | 7114篇 |
排序方式: 共有10000条查询结果,搜索用时 187 毫秒
41.
42.
The Pedagogical Challenges of Teaching High School Bioethics: Insights from the Exploring Bioethics Curriculum 下载免费PDF全文
Mildred Z. Solomon David Vannier Jeanne Ting Chowning Jacqueline S. Miller Katherine F. Paget 《The Hastings Center report》2016,46(1):11-18
A belief that high school students have the cognitive ability to analyze and assess moral choices and should be encouraged to do so but have rarely been helped to do so was the motivation for developing Exploring Bioethics, a six‐module curriculum and teacher guide for grades nine through twelve on ethical issues in the life sciences. A multidisciplinary team of bioethicists, science educators, curriculum designers, scientists, and high school biology teachers worked together on the curriculum under a contract between the National Institutes of Health and Education Development Center, a nonprofit research and development organization with a long history of innovation in science education. At the NIH, the Department of Bioethics within the Clinical Center and the Office of Science Education within the Office of the Director guided the project.Our overarching goal for Exploring Bioethics was to introduce students to bioethics as a field of inquiry and to enable them to develop ethical reasoning skills so they could move beyond “gut reactions” to more nuanced positions. 相似文献
43.
44.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
45.
46.
47.
R. Di Raimondo J. Sanz-Esporrn R. Pl I. Sanz-Martn F. Luengo F. Vignoletti J. Nuez Mariano Sanz 《Clinical oral investigations》2020,24(7):2351-2361
To evaluate the changes in alveolar contour after guided bone regeneration (GBR) with two different combinations of biomaterials in dehiscence defects arou 相似文献
48.
49.
Bhavana Pothuri Allison L. Brodsky Joseph A. Sparano Stephanie V. Blank Mimi Kim Dawn L. Hershman Amy Tiersten Brian F. Kiesel Jan H. Beumer Leonard Liebes Franco Muggia 《Cancer chemotherapy and pharmacology》2020,85(4):741-751
Poly(ADP-ribosyl) polymerases (PARPs) are nuclear enzymes with roles in DNA damage recognition and repair. PARP1 inhibition enhances the effects of DNA-damaging agents like doxorubicin. We sought to determine the recommended phase two dose (RP2D) of veliparib with pegylated liposomal doxorubicin (PLD) in breast and recurrent gynecologic cancer patients. Veliparib and PLD were administered in a standard phase 1, 3 + 3 dose-escalation design starting at 50 mg veliparib BID on days 1–14 with PLD 40 mg/mg2 on day 1 of a 28-day cycle. Dose escalation proceeded in two strata: A (prior PLD exposure) and B (no prior PLD exposure). Patients underwent limited pharmacokinetic (PK) sampling; an expansion PK cohort was added. 44 patients with recurrent ovarian or triple negative breast cancer were enrolled. Median age 56 years; 23 patients BRCA mutation carriers; median prior regimens four. Patients received a median of four cycles of veliparib/PLD. Grade 3/4 toxicities were observed in 10% of patients. Antitumor activity was observed in both sporadic and BRCA-deficient cancers. Two BRCA mutation carriers had complete responses. Two BRCA patients developed oral squamous cell cancers after completing this regimen. PLD exposure was observed to be higher when veliparib doses were > 200 mg BID. The RP2D is 200 mg veliparib BID on days 1–14 with 40 mg/m2 PLD on day 1 of a 28-day cycle. Anti-tumor activity was seen in both strata. However, given development of long-term squamous cell cancers and the PK interaction observed, efforts should focus on other targeted combinations to improve efficacy. 相似文献